72 related articles for article (PubMed ID: 36412679)
21. True-Positive
Fleming MT; Hermsen R; Purysko AS; Chau A; Davis P; Chapin BF; Schuster DM
J Nucl Med; 2024 May; ():. PubMed ID: 38782456
[No Abstract] [Full Text] [Related]
22. PSMA-Targeted PET Radiotracer [
Ismail MS; Peters DE; Rowe SP; Salavati A; Sharma S; Anders RA; Pomper M; Slusher BS; Selaru FM
Clin Exp Gastroenterol; 2023; 16():237-247. PubMed ID: 38090679
[TBL] [Abstract][Full Text] [Related]
23. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study.
García Vicente AM; Lucas Lucas C; Pérez-Beteta J; Borrelli P; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM
Sci Rep; 2024 Feb; 14(1):3001. PubMed ID: 38321201
[TBL] [Abstract][Full Text] [Related]
24. Metastatic Superscan in
Singh MM; Verma S; Kakkar L; Deswal S; Thakur PB
Mol Imaging Radionucl Ther; 2024 Feb; 33(1):38-39. PubMed ID: 38390777
[TBL] [Abstract][Full Text] [Related]
25. Uptake of
Rowe SP; Deville C; Paller C; Cho SY; Fishman EK; Pomper MG; Ross AE; Gorin MA
Tomography; 2015 Dec; 1(2):81-84. PubMed ID: 26807444
[TBL] [Abstract][Full Text] [Related]
26. Optimization of PET protocol and interrater reliability of
Piron S; De Man K; Schelfhout V; Van Laeken N; Kersemans K; Achten E; De Vos F; Ost P
EJNMMI Res; 2020 Feb; 10(1):14. PubMed ID: 32095919
[TBL] [Abstract][Full Text] [Related]
27. An Automated Deep Learning-Based Framework for Uptake Segmentation and Classification on PSMA PET/CT Imaging of Patients with Prostate Cancer.
Li Y; Imami MR; Zhao L; Amindarolzarbi A; Mena E; Leal J; Chen J; Gafita A; Voter AF; Li X; Du Y; Zhu C; Choyke PL; Zou B; Jiao Z; Rowe SP; Pomper MG; Bai HX
J Imaging Inform Med; 2024 Apr; ():. PubMed ID: 38587770
[TBL] [Abstract][Full Text] [Related]
28. A Systematic Review on Artificial Intelligence Evaluating Metastatic Prostatic Cancer and Lymph Nodes on PSMA PET Scans.
Liu J; Cundy TP; Woon DTS; Lawrentschuk N
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339239
[TBL] [Abstract][Full Text] [Related]
29. Comments on Study of "Performance of 18F-DCFPyL PET/CT in Primary Prostate Cancer Diagnosis, Gleason Grading and D'Amico Classification: A Radiomics-Based Study".
Kreissl MC
Phenomics; 2023 Dec; 3(6):639-641. PubMed ID: 38223682
[No Abstract] [Full Text] [Related]
30. PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.
Dondi F; Lazzarato A; Gorica J; Guglielmo P; Borgia F; Filice R; Vento A; Pacella S; Camedda R; Caracciolo M; De Feo MS; Mammucci P; Frantellizzi V; Ortolan N; Fiasconaro E; Urso L; Evangelista L; Laudicella R; Santo G;
Life (Basel); 2023 Feb; 13(3):. PubMed ID: 36983767
[TBL] [Abstract][Full Text] [Related]
31. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
Lengana T; Lawal I; Janse Van Rensburg C; Mokoala K; Moshokoa E; Mazibuko S; Van de Wiele C; Maes A; Vorster M; Sathekge MM
Nuklearmedizin; 2022 Apr; 61(2):120-129. PubMed ID: 35421900
[TBL] [Abstract][Full Text] [Related]
32. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
33. Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on
Garg T; Werner RA; Chung HW; Khatri W; Pienta KJ; Pomper MG; Gorin MA; Saad E; Rowe SP
Tomography; 2022 Oct; 8(6):2639-2647. PubMed ID: 36412679
[TBL] [Abstract][Full Text] [Related]
34.
Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
[TBL] [Abstract][Full Text] [Related]
35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
36. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
